IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

COLOMBO, MASSIMO GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 32.762
NA - Nord America 22.032
AS - Asia 20.933
SA - Sud America 1.900
AF - Africa 399
OC - Oceania 97
Continente sconosciuto - Info sul continente non disponibili 41
Totale 78.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.340
GB - Regno Unito 14.099
CN - Cina 6.505
SG - Singapore 6.141
DE - Germania 4.196
IT - Italia 3.445
SE - Svezia 2.516
RU - Federazione Russa 2.435
HK - Hong Kong 1.788
FR - Francia 1.416
VN - Vietnam 1.414
UA - Ucraina 1.346
BR - Brasile 1.255
IN - India 1.106
TR - Turchia 1.042
BD - Bangladesh 962
IE - Irlanda 865
KR - Corea 852
NL - Olanda 763
FI - Finlandia 635
EU - Europa 578
CA - Canada 497
CO - Colombia 335
PL - Polonia 273
JP - Giappone 220
ID - Indonesia 209
GR - Grecia 169
DK - Danimarca 142
AR - Argentina 124
BE - Belgio 103
IQ - Iraq 95
CI - Costa d'Avorio 94
MX - Messico 84
AU - Australia 72
ES - Italia 69
TW - Taiwan 64
UZ - Uzbekistan 61
PK - Pakistan 58
PH - Filippine 56
ZA - Sudafrica 52
EG - Egitto 51
MA - Marocco 47
SA - Arabia Saudita 47
TH - Thailandia 45
AT - Austria 44
VE - Venezuela 42
CL - Cile 41
EC - Ecuador 41
RO - Romania 41
IL - Israele 34
CH - Svizzera 32
MY - Malesia 31
JO - Giordania 29
AE - Emirati Arabi Uniti 27
CZ - Repubblica Ceca 22
KE - Kenya 22
TN - Tunisia 22
JM - Giamaica 21
HU - Ungheria 18
IR - Iran 18
NP - Nepal 18
PE - Perù 18
NZ - Nuova Zelanda 17
PY - Paraguay 17
PT - Portogallo 16
UY - Uruguay 16
KZ - Kazakistan 15
DZ - Algeria 14
CR - Costa Rica 13
LT - Lituania 13
ET - Etiopia 12
NO - Norvegia 12
GE - Georgia 11
GT - Guatemala 11
UG - Uganda 11
AZ - Azerbaigian 10
SL - Sierra Leone 10
TT - Trinidad e Tobago 10
AL - Albania 9
LV - Lettonia 9
MD - Moldavia 9
PS - Palestinian Territory 9
BG - Bulgaria 8
BO - Bolivia 8
BY - Bielorussia 8
EE - Estonia 8
PA - Panama 8
SI - Slovenia 8
XK - ???statistics.table.value.countryCode.XK??? 8
DO - Repubblica Dominicana 7
GH - Ghana 7
KG - Kirghizistan 7
LB - Libano 7
LU - Lussemburgo 7
BS - Bahamas 6
LA - Repubblica Popolare Democratica del Laos 6
LK - Sri Lanka 6
LY - Libia 6
MK - Macedonia 6
SC - Seychelles 6
Totale 78.558
Salva come PNG Salva come JPEG
Città #
Southend 13.291
Singapore 3.453
Chandler 1.901
Ashburn 1.757
Hong Kong 1.685
Seattle 1.515
Beijing 1.482
San Jose 1.259
Jacksonville 1.095
Princeton 1.038
Milan 977
Dublin 842
Wilmington 831
Frankfurt am Main 712
Council Bluffs 593
Dallas 555
Nanjing 553
Bengaluru 550
Mountain View 537
Redmond 530
Los Angeles 517
Ann Arbor 502
Santa Clara 481
Lauterbourg 425
Serra 416
Ho Chi Minh City 407
Dearborn 396
Hanoi 378
Boardman 376
New York 364
Sakarya 362
Des Moines 356
Andover 349
Woodbridge 349
Fairfield 327
Buffalo 318
Toronto 315
Shanghai 307
Bogotá 304
Moscow 303
Somerville 300
Houston 252
Guangzhou 241
Warsaw 236
Hanover 227
Munich 199
Hefei 188
Jinan 178
Tianjin 158
Shenyang 148
Phoenix 143
Saint Petersburg 143
Cangzhou 139
Nanchang 137
Tokyo 134
Helsinki 133
Cambridge 121
Columbus 121
Athens 112
Rome 110
The Dalles 109
Berlin 107
Changsha 106
São Paulo 104
Eitensheim 103
Hebei 99
Redwood City 95
Abidjan 93
Brussels 93
Bitonto 91
Grafing 91
Shenzhen 83
Hangzhou 81
Kunming 80
Turin 80
Jakarta 74
Seoul 72
Mumbai 69
Zhengzhou 69
Jiaxing 68
San Diego 65
Kiez 63
Chicago 62
Sunnyvale 61
Da Nang 60
Haiphong 60
Naples 58
Hamburg 57
Auburn Hills 55
Fuzhou 55
Istanbul 55
London 55
Nuremberg 54
Ottawa 45
Belo Horizonte 43
Nürnberg 43
Margão 42
Chengdu 41
Medford 40
Lanzhou 39
Totale 48.948
Salva come PNG Salva come JPEG
Nome #
Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection 709
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 528
Multimodality treatment of hepatocellular carcinoma : How field practice complies with international recommendations 465
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 429
Global patterns of hepatocellular carcinoma management from diagnosis to Death : the BRIDGE Study 407
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 399
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 396
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 394
No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants 378
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B 358
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 351
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 349
Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy 332
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 310
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B 308
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 308
Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis 305
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 303
Combined lamivudine and adefovir dipivoxil treatment allows safe and long-term compath-1H therapy in refractory B-cell chronic lymphocytic leukemia with HBV reactivation 303
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H 296
Donor/recipient match of IL28B to predict interferon response in recurrent hepatitis C 293
A 28-Year Study of the Course of Hepatitis Delta Infection : A Risk Factor for Cirrhosis and Hepatocellular Carcinoma 291
Chromogranin A levels in chronic liver disease and hepatocellular carcinoma 288
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 287
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 286
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma : multicentre, open-label, phase II safety study 286
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma 282
Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease 276
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study 274
High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta 272
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 270
Prevalence of serum antinuclear antibodies (ANA) after liver transplant in HCV and HBV recipients is associated with different clinical profiles 269
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 269
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 268
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity 263
The natural history of compensated cirrhosis due to hepatitis C virus : A 17-year cohort study of 214 patients 261
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 261
Accuracy of two new predictive models in assessing fibrosis in chronic hepatitis C (CHC) 259
PNPLA3 I148M polymorphism, etiology, and clinical features of hepatocellular carcinoma 257
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 255
Stifness epatica e splenica misurate con l’elastografia transiente : fattibilita’ e ruolo nei pazienti con emoglobinopatia 254
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 254
Males with primary biliary cirrhosis manifest enhanced rates of Y chromosome loss compared to healthy subjects 253
Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection 248
Serum nuclear autoantibodies with nucleolar pattern in chronic liver diseases 247
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 247
Serum expression of lectin reactive alphafetoprotein, des-gamma-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma 246
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 246
A prospective study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of hepatocellular carcinoma 245
Anemia during pegylated interferon-ribavirin therapy results from both increase suppression of erythroid differentiation and hemolysis 244
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma 243
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 242
Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor 242
Inhibition of HBV-replication by combined treatment of lamivudine and adefovir dipivoxil allows long-term campath-1H therapy in refractory B-cell chronic lymphoblastic leukemia 238
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 238
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 238
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance 235
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 235
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 235
Y chromosome loss in male patients with primary biliary cirrhosis 235
Management of Biliary Anastomotic Strictures After Liver Transplantation (BASALT Study): a Nationwide Italian Survey 235
Evaluating liver fibrosis in chronic hepatitis c (CHC), accuracy of two new predictive models 234
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 234
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 234
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 231
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis 231
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 231
Long-term suppression of hepatitis B e antigen negative chronic hepatitis B by 24 month interferon therapy 230
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 230
Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C 228
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease 227
Liver fibrosis in adult thalassemia patients assessed by transient elastography 227
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 227
Combination therapy with adefovir dipivoxil (ADV)and lamivudine (LAM) in LAM-resistant patients enlisted for liver transplantation 226
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 225
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 225
Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B 225
A sequential predictive algorithm combining APRI and transient elastography (TE) for diagnosing liver fibrosis in chronic hepatitis C 224
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 224
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis 223
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 222
Severe hepatic fibrosis in chronic hepatitis C 221
Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension 221
Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis 221
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients 221
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 221
The candidate HCV E1E2MF59 vaccine is safe in chronic hepatitis C patients and accellerates the second phase viral decline upon primary response to peg-interferon-2A/ribavirin therapy 220
Successful treatment of hepatocellular carcinoma (HCC) with transchateter arterial embolization (TAE) with microspheres (embosphere) 219
Transient elastography in patients with celiac disease : a noninvasive method to detect liver involvement associated with celiac disease 219
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 219
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 218
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients 218
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis 218
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 217
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 216
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 216
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 215
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 215
Serum nuclear autoantibodies with nucleolar pattern in chronic liver diseases 214
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 214
Totale 26.896
Salva come PNG Salva come JPEG
Categoria #
all - tutte 210.662
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210.662
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021559 0 0 0 0 0 0 0 0 0 0 0 559
2021/20225.115 472 187 120 300 299 327 536 389 454 691 290 1.050
2022/20236.283 831 626 545 784 771 1.326 113 331 608 77 192 79
2023/20243.755 96 308 162 217 1.101 232 174 208 115 193 402 547
2024/20258.796 346 1.061 176 1.022 731 267 195 972 493 709 828 1.996
2025/202618.501 1.935 938 1.996 1.292 1.816 1.337 2.220 1.071 1.942 1.477 2.051 426
Totale 82.464